Merck &Co. has won approval from the powerful Food and Drug Administration to sell a novel treatment for type 2 diabetes . The pill, known as Janumet, targets the cause of type 2 and is a combined form of Januvia.
Januvia has been a blockbuster drug for Merck, who are the third biggest maker of prescription drugs in the USA. Janumet combines Januvia and the ubiquitous metformin to create a powerful treatment of type 2 diabetes. Janumet will hit the US diabetes market this month, and may also be approved for distribution in Europe following approval.
The diabetes drug market is enormous, with a number of major companies jostling for the top spot. The fortunes of the big corporation rise and fall, and can be governed by the success or failure of a single drug. Eli Lilly, Merck, Glaxo and others are constantly seeking new drug developments to give them the edge over their competition. It seems that Merck is doing particularly well with its recent diabetes additions.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…